Papillomavirus Infections
Information
- Disease name
- Papillomavirus Infections
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05285826 | Active, not recruiting | Phase 3 | Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) | February 18, 2022 | May 25, 2029 |
| NCT05450705 | Active, not recruiting | Phase 3 | V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) | July 22, 2022 | August 3, 2029 |
| NCT04199689 | Active, not recruiting | Phase 3 | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | February 27, 2020 | September 21, 2026 |
| NCT04724980 | Active, not recruiting | Phase 1/Phase 2 | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | March 16, 2021 | June 2, 2026 |
| NCT05580341 | Active, not recruiting | Phase 3 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | September 1, 2022 | December 2023 |
| NCT03675256 | Active, not recruiting | Phase 4 | The KEN SHE Study on HPV-vaccine Efficacy | December 19, 2018 | February 15, 2024 |
| NCT04708041 | Active, not recruiting | Phase 3 | Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) | March 15, 2021 | June 18, 2029 |
| NCT03998254 | Active, not recruiting | Phase 3 | Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | June 26, 2019 | March 31, 2028 |
| NCT03903562 | Active, not recruiting | Phase 3 | Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) | April 27, 2019 | January 18, 2025 |
| NCT00685412 | Completed | Phase 1 | Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 | May 2008 | March 2011 |
| NCT00743392 | Completed | HPV Infections in Older Women | July 2008 | May 2011 | |
| NCT00973856 | Completed | N/A | Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands | September 2009 | January 2012 |
| NCT01073293 | Completed | Phase 3 | A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) | April 22, 2010 | June 16, 2011 |
| NCT01101828 | Completed | Self-collected Swabs for HPV Testing in 18-24 Year Old Women | April 2010 | January 2011 | |
| NCT01245764 | Completed | Phase 3 | GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) | March 21, 2011 | April 15, 2013 |
| NCT01254643 | Completed | Phase 3 | A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | January 12, 2011 | August 10, 2013 |
| NCT01295242 | Completed | Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM) | February 2011 | August 2012 | |
| NCT01894425 | Completed | Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation | May 2014 | December 2016 | |
| NCT02346227 | Completed | Phase 3 | Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix | January 2015 | August 2018 |
| NCT02535104 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) | February 2016 | September 2016 |
| NCT02631863 | Completed | Phase 2 | Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) | March 22, 2016 | November 24, 2018 |
| NCT02845739 | Completed | N/A | PApillomavirus in REnal Transplant Patient | January 1, 2011 | November 10, 2017 |
| NCT02897232 | Completed | Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination | July 2016 | April 2020 | |
| NCT03487549 | Completed | Phase 2 | Cantharidin and Occlusion in Verruca Epithelium | March 27, 2018 | July 15, 2019 |
| NCT03546842 | Completed | Phase 3 | Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | June 29, 2018 | January 29, 2019 |
| NCT06439433 | Completed | Phase 2 | ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection | May 31, 2021 | March 6, 2024 |
| NCT00157950 | Completed | Phase 3 | Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) | October 2005 | June 2006 |
| NCT00188292 | Completed | Screening for HIV-Associated Anal Cancer | August 2002 | June 2012 | |
| NCT00194311 | Completed | Human Papillomavirus (HPV) Infection in Pregnancy | April 2005 | August 2007 | |
| NCT00365716 | Completed | Phase 2 | Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) | May 2000 | September 2009 |
| NCT00380367 | Completed | Phase 3 | Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) | May 3, 2007 | February 4, 2008 |
| NCT00461877 | Completed | High-Risk HPV Infections in Women Aged 25 to 65 | March 2007 | December 2008 | |
| NCT00496626 | Completed | Phase 3 | An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) | July 20, 2008 | February 28, 2009 |
| NCT00549250 | Completed | Human Papillomavirus 6/11 in the Lower Airway of Neonates | November 2007 | May 2010 | |
| NCT03584308 | Completed | Phase 2 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | October 15, 2015 | December 15, 2018 |
| NCT03929172 | Completed | Phase 1 | A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects | February 28, 2019 | May 29, 2020 |
| NCT03981822 | Completed | Phase 2 | A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | June 25, 2019 | July 8, 2020 |
| NCT04000503 | Completed | N/A | Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge) | August 1, 2019 | October 31, 2022 |
| NCT04072913 | Completed | N/A | Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix | October 10, 2007 | January 31, 2011 |
| NCT04772534 | Completed | Phase 3 | Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) | May 17, 2021 | April 6, 2024 |
| NCT05119855 | Completed | Phase 3 | Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) | March 28, 2022 | December 12, 2023 |
| NCT06399341 | Completed | Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). | September 1, 2021 | April 30, 2023 | |
| NCT00092547 | Completed | Phase 3 | A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) | October 8, 2003 | June 1, 2015 |
| NCT04910438 | Recruiting | Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. | June 24, 2021 | December 2024 | |
| NCT05797246 | Recruiting | Phase 2 | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) | August 2, 2023 | November 2, 2026 |
| NCT06371118 | Recruiting | N/A | HPV Self-sampling for Women Who do Not Attend Cervical Cancer Screening Programme | April 15, 2024 | November 2024 |
| NCT04124198 | Recruiting | N/A | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | March 1, 2019 | January 2029 |
| NCT02858310 | Recruiting | Phase 1/Phase 2 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | January 27, 2017 | January 1, 2026 |
| NCT04015336 | Terminated | Phase 2 | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | July 6, 2020 | July 15, 2020 |
| NCT00117884 | Terminated | Phase 2 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. | April 2006 | June 2008 |
| NCT00312286 | Terminated | Phase 2 | Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. | April 2006 | June 2008 |
| NCT01355003 | Terminated | GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) | February 2008 | June 2010 | |
| NCT00365729 | Unknown status | Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men | October 2003 | January 2018 | |
| NCT03548740 | Unknown status | Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection | September 1, 2018 | May 20, 2020 | |
| NCT04671823 | Unknown status | Changes in the Prevalence of Oncogenic HPV Types | December 2020 | March 31, 2022 | |
| NCT00421486 | Unknown status | Oral Human Papillomavirus Infection in HIV-infected Men | March 2006 | January 2018 | |
| NCT04694495 | Unknown status | HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study | November 12, 2020 | December 12, 2022 | |
| NCT01709448 | Unknown status | Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV | January 2009 | March 2014 | |
| NCT04115787 | Unknown status | Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN | October 14, 2019 | December 28, 2019 | |
| NCT00124878 | Unknown status | Phase 3 | Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community | August 2003 | September 2009 |
| NCT00501189 | Withdrawn | Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities | August 2007 | July 2009 | |
| NCT04044950 | Withdrawn | Phase 2 | A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer | July 29, 2019 | September 17, 2020 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D030361